Gilead Sales Double on $1,000 Hepatitis C Pills

A machine works on the purification of a potential hepatitis C drug at the Gilead Sciences lab in Foster City, Calif., in February 2012 Photograph by David Paul Morris/Bloomberg

It turns out you can make real money selling $1,000 pills. That’s what Gilead Sciences discovered in the quarter since the debut of Sovaldi, its hepatitis C treatment that has drawn attention for both its advances over existing therapies and its high price tag.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.